Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 10/2007

01-12-2007 | Original Paper

IL6 genotypes and colon and rectal cancer

Authors: Martha L. Slattery, Roger K. Wolff, Jennifer S. Herrick, Bette J. Caan, John D. Potter

Published in: Cancer Causes & Control | Issue 10/2007

Login to get access

Abstract

Inflammation appears to play a key role in the development of colorectal cancer (CRC). In this study we examine factors involved in the regulation of inflammation and risk of CRC. Data from a multi-center case–control study of colon (N = 1579 cases and N = 1977 controls) and rectal (N = 794 cases and N = 1005 controls) cancer were used to evaluate the association between the rs1800795 and rs1800796 IL6 polymorphisms and CRC. We evaluated the joint effects of IL6 single nucleotide polymorphisms and regular use of aspirin/NSAIDs and vitamin D receptor (VDR) genotype. Having a C allele of the rs1800796 IL6 polymorphisms and the GG genotype of the rs1800795 IL6 polymorphisms was associated with a statistically significantly reduced the risk of colon (OR 0.76 95% CI 0.57, 1.00), but not rectal (OR 1.49 95% CI 1.02,2.16) cancer. Both IL6 polymorphisms were associated with significant interaction with current use of aspirin/NSAIDs to alter risk of colon cancer: individuals with a C allele in either polymorphism who were current users of aspirin/NSAIDs had the lowest colon cancer risk. CRC risk also was associated with an interaction between VDR and IL6 genotypes that was modified by current use of aspirin/NSAIDs. This study provides further support for inflammation-related factors in the etiology of CRC. Other studies are needed to explore other genes in this and other inflammation-related pathways.
Literature
1.
Devroede GJ, Taylor WF, Sauer WG, Jackman RJ, Stickler GB (1971) Cancer risk and life expectancy of children with ulcerative colitis. N Engl J Med 285:17–21PubMedCrossRef
2.
3.
Smalley W, Ray WA, Daugherty J, Griffin MR (1999) Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 159:161–166PubMedCrossRef
4.
Collet JP, Sharpe C, Belzile E, Boivin JF, Hanley J, Abenhaim L (1999) Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 81:62–68PubMedCrossRef
5.
Marnett LJ (1992) Aspirin and the potential role of prostaglandins in colon cancer. Cancer Research 52:5575–5589PubMed
6.
Bozcuk H, Uslu G, Samur M, Yildiz M, Ozben T, Ozdogan M, Artac M, Altunbas H, Akan I, Savas B (2004) Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine 27:58–65PubMedCrossRef
7.
Mantovani G, Maccio A, Madeddu C, Mura L, Gramignano G, Lusso MR, Mulas C, Mudu MC, Murgia V, Camboni P, Massa E, Ferreli L, Contu P, Rinaldi A, Sanjust E, Atzei D, Elsener B (2002) Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. Int J Cancer 98:84–91PubMedCrossRef
8.
Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P, Dirix LY (2003) Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 103:642–646PubMedCrossRef
9.
Gunter MJ, Stolzenberg-Solomon R, Cross AJ, Leitzmann MF, Weinstein S, Wood RJ, Virtamo J, Taylor PR, Albanes D, Sinha R (2006) A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 66:2483–2487PubMedCrossRef
10.
Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ (2004) C-reactive protein and the risk of incident colorectal cancer. Jama 291:585–590PubMedCrossRef
11.
Helzlsouer KJ, Erlinger TP, Platz EA (2006) C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. Eur J Cancer 42:704–707PubMedCrossRef
12.
Ito Y, Suzuki K, Tamakoshi K, Wakai K, Kojima M, Ozasa K, Watanabe Y, Kawado M, Hashimoto S, Suzuki S, Tokudome S, Toyoshima H, Hayakawa N, Kato K, Watanabe M, Ohta Y, Maruta M, Tamakoshi A (2005) Colorectal cancer and serum C-reactive protein levels: a case–control study nested in the JACC Study. J Epidemiol 15(Suppl 2):S185–S189PubMedCrossRef
13.
Zhang SM, Buring JE, Lee IM, Cook NR, Ridker PM (2005) C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med 142:425–432PubMed
14.
Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL (2003) Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 88:255–259PubMedCrossRef
15.
Bennermo M, Held C, Stemme S, Ericsson CG, Silveira A, Green F, Tornvall P (2004) Genetic predisposition of the Interleukin-6 response to inflammation: implications for a variety of major diseases? Clin Chem
16.
Mohlig M, Boeing H, Spranger J, Osterhoff M, Kroke A, Fisher E, Bergmann MM, Ristow M, Hoffmann K, Pfeiffer AF (2004) Body mass index and C-174G interleukin-6 promoter polymorphism interact in predicting type 2 diabetes. J Clin Endocrinol Metab 89:1885–1890PubMedCrossRef
17.
Slattery ML, Curtin K, Baumgartner R, Sweeney C, Byers T, Giuliano AR, Baumgartner KB, Wolff RR (2007) IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern united states. Cancer Epidemiol Biomarkers Prev 16:747–755PubMedCrossRef
18.
Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369–1376PubMedCrossRef
19.
Theodoropoulos G, Papaconstantinou I, Felekouras E, Nikiteas N, Karakitsos P, Panoussopoulos D, Lazaris A, Patsouris E, Bramis J, Gazouli M (2006) Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J Gastroenterol 12:5037–5043PubMed
20.
Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G, Canzian F (2003) Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 63:3560–3566PubMed
21.
Hayes CE, Nashold FE, Spach KM, Pedersen LB (2003) The immunological functions of the vitamin D endocrine system. Cell Mol Biol (Noisy-le-grand) 49:277–300
22.
Froicu M, Weaver V, Wynn TA, McDowell MA, Welsh JE, Cantorna MT (2003) A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol 17:2386–2392PubMedCrossRef
23.
Park K, Woo M, Nam J, Kim JC. Start codon polymorphisms in the vitamin D receptor and colorectal cancer risk. Cancer Letters (in Press, corrected proof)
24.
Kim HS, Newcomb PA, Ulrich CM, Keener CL, Bigler J, Farin FM, Bostick RM, Potter JD (2001) Vitamin D receptor polymorphism and the risk of colorectal adenomas: evidence of interaction with dietary vitamin D and calcium. Cancer Epidemiol Biomarkers Prev 10:869–874PubMed
25.
Ingles SA, Wang J, Coetzee GA, Lee ER, Frankl HD, Haile RW (2001) Vitamin D receptor polymorphisms and risk of colorectal adenomas (United States). Cancer Causes Control 12:607–614PubMedCrossRef
26.
Slattery ML, Yakumo K, Hoffman M, Neuhausen S (2001) Variants of the VDR gene and risk of colon cancer (United States). Cancer Causes Control 12:359–364CrossRef
27.
Wong HL, Seow A, Arakawa K, Lee HP, Yu MC, Ingles SA (2003) Vitamin D receptor start codon polymorphism and colorectal cancer risk: effect modification by dietary calcium and fat in Singapore Chinese. Carcinogenesis 24:1091–1095PubMedCrossRef
28.
Peters U, McGlynn KA, Chatterjee N, Gunter E, Garcia-Closas M, Rothman N, Sinha R (2001) Vitamin D, calcium, and vitamin D receptor polymorphism in colorectal adenomas. Cancer Epidemiol Biomarkers Prev 10:1267–1274PubMed
29.
Whitfield GK, Remus LS, Jurutka PW, Zitzer H, Oza AK, Dang HT, Haussler CA, Galligan MA, Thatcher ML, Encinas Dominguez C, Haussler MR (2001) Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol 177:145–159PubMedCrossRef
30.
Jurutka PW, Remus LS, Whitfield GK, Thompson PD, Hsieh JC, Zitzer H, Tavakkoli P, Galligan MA, Dang HT, Haussler CA, Haussler MR (2000) The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol Endocrinol 14:401–420PubMedCrossRef
31.
http://seer.cancer.gov/publications/ethnicity/colorect.pdf
32.
Slattery ML, Potter J, Caan B, Edwards S, Coates A, Ma KN, Berry TD (1997) Energy balance and colon cancer–beyond physical activity. Cancer Res 57:75–80PubMed
33.
Edwards S, Slattery ML, Mori M, Berry TD, Caan BJ, Palmer P, Potter JD (1994) Objective system for interviewer performance evaluation for use in epidemiologic studies. Am J Epidemiol 140:1020–1028PubMed
34.
Slattery ML, Caan BJ, Duncan D, Berry TD, Coates A, Kerber R (1994) A computerized diet history questionnaire for epidemiologic studies. J Am Diet Assoc 94:761–766PubMedCrossRef
35.
Watanabe E, Hirasawa H, Oda S, Matsuda K, Hatano M, Tokuhisa T (2005) Extremely high interleukin-6 blood levels and outcome in the critically ill are associated with tumor necrosis factor- and interleukin-1-related gene polymorphisms. Crit Care Med 33:89–97; discussion 242–243PubMedCrossRef
36.
Sweeney C, Curtin K, Murtaugh MA, Caan BJ, Potter JD, Slattery ML (2006) Haplotype analysis of common vitamin D receptor variants and colon and rectal cancers. Cancer Epidemiol Biomarkers Prev 15:744–749PubMedCrossRef
37.
Slattery ML KA, Levin TR (1993) Factors associated with colorectal cancer screening in a population-based study: the impact of gender, health care source, and time. Submitted, March 2003.Potter JD, Slattery ML, Bostick RM, Gapstur SM. Colon cancer a review of the epidemiology. Epidemiol Rev 15:499–545
38.
Camp NJ, Slattery ML (2002) Classification tree analysis: a statistical tool to investigate risk factor interactions with an example for colon cancer (United States). Cancer Causes Control 13:813–823PubMedCrossRef
39.
Slattery ML, Samowitz W, Hoffman M, Ma KN, Levin TR, Neuhausen S (2004) Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. Cancer Epidemiol Biomarkers Prev 13:538–545PubMed
40.
Slattery ML, Curtin K, Wolff R, Ma KN, Sweeney C, Murtaugh M, Potter JD, Levin TR, Samowitz W (2006) PPARgamma and colon and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States). Cancer Causes Control 17:239–249PubMedCrossRef
41.
Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, Willett WC, Selhub J, Hennekens CH, Rozen R (1997) Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 57:1098–1102PubMed
42.
Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293:1673–1677PubMedCrossRef
43.
Fang V, Foye WO, Robinson SM, Jenkins HJ (1968) Hypoglycemic activity and chemical structure of the salicylates. J Pharm Sci 57:2111–2116PubMedCrossRef
44.
Graef I, Gibbons DM (1960) Salicylates and carbohydrate metabolism. Diabetes 9:416–418PubMed
45.
Powell ED, Field RA (1966) Studies on salicylates and complement in diabetes. Diabetes 15:730–733PubMed
46.
McRae JR, Chen M, Robertson RP (1980) Improvement of defective insulin responses to glucose, arginine, and beta-adrenergic stimulation in diabetics by sodium salicylate. Adv Prostaglandin Thromboxane Res 8:1287–1289PubMed
47.
48.
Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI (2002) Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109:1321–1326PubMedCrossRef
49.
Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N (2006) Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev 15:1126–1131PubMedCrossRef
50.
Thomas MG, Tebbutt S, Williamson RC (1992) Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line. Gut 33:1660–1663PubMedCrossRef
51.
Ogunkolade BW, Boucher BJ, Prahl JM, Bustin SA, Burrin JM, Noonan K, North BV, Mannan N, McDermott MF, DeLuca HF, Hitman GA (2002) Vitamin D receptor (VDR) mRNA and VDR protein levels in relation to vitamin D status, insulin secretory capacity, and VDR genotype in Bangladeshi Asians. Diabetes 51:2294–2300PubMedCrossRef
52.
Rozen F, Pollak M (1999) Inhibition of insulin-like growth factor I receptor signaling by the vitamin D analogue EB1089 in MCF-7 breast cancer cells: A role for insulin-like growth factor binding proteins. Int J Oncol 15:589–594PubMed
53.
Zeitz U, Weber K, Soegiarto DW, Wolf E, Balling R, Erben RG (2003) Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. Faseb J 17:509–511PubMed
54.
Mahon BD, Wittke A, Weaver V, Cantorna MT (2003) The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem 89:922–932PubMedCrossRef
55.
Bhalla AK, Amento EP, Clemens TL, Holick MF, Krane SM (1983) Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab 57:1308–1310PubMedCrossRef
56.
Bemiss CJ, Mahon BD, Henry A, Weaver V, Cantorna MT (2002) Interleukin-2 is one of the targets of 1,25-dihydroxyvitamin D3 in the immune system. Arch Biochem Biophys 402:249–254PubMedCrossRef
57.
Yee YK, Chintalacharuvu SR, Lu J, Nagpal S Vitamin D receptor modulators for inflammation, cancer (2005) Mini Rev Med Chem 5:761–778
Metadata
Title
IL6 genotypes and colon and rectal cancer
Authors
Martha L. Slattery
Roger K. Wolff
Jennifer S. Herrick
Bette J. Caan
John D. Potter
Publication date
01-12-2007
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 10/2007
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-007-9049-x

Other articles of this Issue 10/2007

Cancer Causes & Control 10/2007 Go to the issue

Original Paper

Nitrate in public water supplies and the risk of renal cell carcinoma

Original Paper

Chronic lymphocytic leukemia radiogenicity: a systematic review

Original Paper

Boron intake and prostate cancer risk

Original Paper

Qualitative age interactions (or effect modification) suggest different cancer pathways for early-onset and late-onset breast cancers

Original Paper

Does excess iron play a role in breast carcinogenesis? an unresolved hypothesis

Original Paper

A prospective study on dietary fat and incidence of prostate cancer (Malmö, Sweden)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits